Anti-Mouse CD51, PE/Cyanine7 conjugated, clone RMV-7

CD51 is a 140 kD protein, also known as alphaV integrin, vitronectin receptor, and integrin alphaV. It is a member of the integrin family, expressed on activated T cells, polymorphonuclear granulocytes, platelets, blastocysts, and osteoclasts. CD51 forms heterodimers by association with integrins beta1, beta3, beta5 or beta6, these complexes then act as receptors for multiple extracellular matrix proteins (ECM). The alphavintegrin heterodimers have varied functions in development, stimulation/activation and homeostasis. The primary ligands for CD51 complexes are fibronectin, fibrinogen, vitronectin, thrombspondin, von Willebrand factor, and CD31. The RMV-7 antibody has been reported to block binding of CD51 to vitronectin, fibronectin, and CD31 in some cell types, as well as blocking LAK cell cytotoxicity. Protein function: The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase- 2, osteopontin, osteomodulin, prothrombin, thrombospondin, TGFB1 and vWF (PubMed:9827803, PubMed:10025398). They recognize the sequence R-G- D in a wide array of ligands. Alpha-V integrins may play a role in embryo implantation, angiogenesis and wound healing (PubMed:9827803). ITGAV:ITGB3 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling. ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1- ERBB signaling. ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling. ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling. ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling. ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling. ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling. ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1. ITGAV:ITGB3 and ITGAV:ITGB6 act as a receptor for fibrillin-1 (FBN1) and mediate R-G-D-dependent cell adhesion to FBN1. Integrin alpha-V/beta-6 or alpha-V/beta-8 (ITGAV:ITGB6 or ITGAV:ITGB8) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation (PubMed:10025398, PubMed:25127859). ITGAV:ITGB3 acts as a receptor for CD40LG. ITGAV:ITGB3 binds to the Lilrb4a/Gp49b receptor and enhances the Lilrb4a-mediated inhibition of mast cell activation (PubMed:11323698). ITGAV:ITGB3 also suppresses marginal zone B cell antibody production through its interaction with Lilrb4a (PubMed:24935931). [The UniProt Consortium]